The effect of triamcinolone acetonide, sodium hyaluronate, and chondroitin sulfate on human endothelial cells: An in vitro study

European Journal of Ophthalmology

Volumn 21, Issue SUPPL.6, 2011, Pages 75-79

  Veritti, Daniele ^a   Perissin, Laura ^a   Zorzet, Sonia ^b   Lanzetta, Paolo ^a  

^a UNIVERSITY OF UDINE   (Italy)

^b UNIVERSITY OF TRIESTE   (Italy)

Author keywords

Angiogenesis; Chondroitin sulfate; Endothelial cells; Sodium hyaluronate; Triamcinolone acetonide

Indexed keywords

BENZYL ALCOHOL; CD31 ANTIGEN; CHONDROITIN SULFATE; HYALURONIC ACID; TRIAMCINOLONE ACETONIDE;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ARTICLE; COLORIMETRY; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; DRUG FORMULATION; ENDOTHELIUM CELL; FIBROBLAST; HUMAN; HUMAN CELL; IMAGE ANALYSIS; IN VITRO STUDY; MYOBLAST; PRIORITY JOURNAL;

ANGIOGENESIS INHIBITORS; ANTI-INFLAMMATORY AGENTS; CELL PROLIFERATION; CELLS, CULTURED; CHONDROITIN SULFATES; DRUG THERAPY, COMBINATION; ENDOTHELIAL CELLS; GLUCOCORTICOIDS; HUMANS; HYALURONIC ACID; TRIAMCINOLONE ACETONIDE;

EID: 79960995603     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.5301/EJO.2010.6060     Document Type: Article

References (23)

1. Javitt JC, Zhou Z, Maguire MG, Fine SL, Willke RJ. Incidence of exudative age-related macular degeneration among elderly Americans. Ophthalmology 2003; 110: 1534-9.
2. Blindness caused by diabetes: Massachusetts, 1987-1994. MMWR Morb Mortal Wkly Rep 1996; 45: 937-41.
3. Miller JW, Adamis AP, Shima DT, et al. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol 1994; 145: 574-84.
4. Bressler SB. Introduction: understanding the role of angiogenesis and antiangiogenic agents in age-related macular degeneration. Ophthalmology 2009; 116: S1-7.
5. Nicholson BP, Schachat AP. A review of clinical trials of anti-VEGF agents for diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2010; 248: 915-30.
6. Valamanesh F, Berdugo M, Sennlaub F, et al. Effects of triamcinolone acetonide on vessels of the posterior segment of the eye. Mol Vis 2009; 15: 2634-48.
7. Zhang X, Bao S, Lai D, Rapkins RW, Gillies MC. Intravitreal triamcinolone acetonide inhibits breakdown of the bloodretinal barrier through differential regulation of VEGF-A and its receptors in early diabetic rat retinas. Diabetes 2008; 57: 1026-33.
8. Ebrahem Q, Minamoto A, Hoppe G, Anand-Apte B, Sears JE. Triamcinolone acetonide inhibits IL-6 and VEGF-induced angiogenesis downstream of the IL-6 and VEGF receptors. Invest Ophthalmol Vis Sci 2006; 47: 4935-41.
9. Tempel C, Gilead A, Neeman M. Hyaluronic acid as an antiangiogenic shield in the preovulatory rat follicle. Biol Reprod 2000; 63: 134-40.
10. Katome T, Naito T, Nagasawa T, Shiota H. Efficacy of combined photodynamic therapy and sub-Tenon's capsule injection of triamcinolone acetonide for age-related macular degeneration. J Med Invest 2009; 56: 116-9.
11. Maberley D. Photodynamic therapy and intravitreal triamcinolone for neovascular age-related macular degeneration: a randomized clinical trial. Ophthalmology 2009; 116: 2149-57.
12. Veritti D, Lanzetta P, Perissin L, Bandello F. Posterior juxtascleral infusion of modified triamcinolone acetonide formulation for refractory diabetic macular edema: oneyear follow-up. Invest Ophthalmol Vis Sci 2009; 50: 2391-7.
13. Beck RW, Edwards AR, Aiello LP, et al. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol 2009; 127: 245-51.
14. Zhou JL, Liu SQ, Qiu B, Hu QJ, Ming JH, Peng H. Effects of hyaluronan on vascular endothelial growth factor and receptor-2 expression in a rabbit osteoarthritis model. J Orthop Sci 2009; 14: 313-9.
15. Kumar S, Witzig TE, Timm M, et al. Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favouring loss of marrow angiogenesis inhibitory. Blood 2004; 104: 1159-65.
16. Chang LK, Gomes NL, Zhou J, Chang S. Physical properties of commercially available formulations of triamcinolone acetonide. Br J Ophthalmol 2009; 93: 1265-6.
17. Li Q, Wang J, Yang L, et al. A morphologic study of retinal toxicity induced by triamcinolone acetonide vehicles in rabbit eyes. Retina 2008; 28: 504-10.
18. Morrison VL, Koh HJ, Cheng L, et al. Intravitreal toxicity of the Kenalog vehicle (benzyl alcohol) in rabbits. Retina 2006; 26: 339-44.
19. Macky TA, Helmy D, El Shazly N. Retinal toxicity of triamcinolone's vehicle (benzyl alcohol): an electrophysiologic and electron microscopic study. Graefes Arch Clin Exp Ophthalmol 2007; 245: 817-24.
20. Aruffo A, Stamenkovic I, Melnick M, Underhill CB, Seed B. CD44 is the principal cell surface receptor for hyaluronate. Cell 1990; 61: 1303-13.
21. Ghosh P, Guidolin D. Potential mechanism of action of intraarticular hyaluronan therapy in osteoarthritis: are the effects molecular weight dependent? Semin Arthritis Rheum 2002; 32: 10-37.
22. Slevin M, West D, Kumar P, Rooney P, Kumar S. Hyaluronan, angiogenesis and malignant disease. Int J Cancer 2004; 109: 793-4.
23. Slevin M, Kumar S, Gaffney J. Angiogenic oligosaccharides of hyaluronan induce multiple signaling pathways affecting vascular endothelial cell mitogenic and wound healing responses. J Biol Chem 2002; 277: 41046-59.